Ruti Aga: Two Years for the Substance, Four for the Forged Paper

In September, the Athletics Integrity Unit announced a six-year sanction for Ruti Aga. Of the entire file, what made me reread most was not the test result, but four details surrounding a single prescription slip. The clinic that issued it does not exist. The signatory holds no medical registration number. That person is a family member of Aga. The slip was written on an old prescription pad taken from a medical facility which confirmed to investigators that the signatory never worked there. Four details, four independent verifications, four sources with no connection to one another. When a case is built and collapses this way, what collapses is not a sophisticated scheme. It is an amateur effort. And that amateurism is itself the data worth analysing, because it speaks to the support structure behind a world-class athlete. Ruti Aga, 32, Ethiopian. She won the 2026 Tokyo Marathon, one of the six World Marathon Majors. She has three runner-up finishes at Majors level; the source does not specify which races, so I leave that in a pending-verification state rather than assigning it. That record is enough to place her among the elite of women's road running in the 2026-2026 window. No more, no less. In the spring of 2026 I sat in front of a screen in Osaka watching the race she won. Back then I logged every kilometre, every aid station, and believed everything on the course could be reduced to a spreadsheet. Seven years later, that spreadsheet is no longer the centre of the story. The pivot of the file is a half marathon in China in March. Aga won. The time is not disclosed in the source. That is the first blind spot and the most regrettable one professionally: without a time, I cannot place the result against any reference scale — not the course record, not her personal best, not the difficulty of the course or the conditions. Any inference about the sporting meaning of that win is speculation. An empty stadium, yet the numbers are still loud. Without a time, the only figures left to analyse are administrative: two years, four years, six years, and one start date — 10 September. Those numbers do not measure speed. They measure the severity of a conduct. The substance was methylprednisolone. Many reports call it a steroid, and that label is wrong by classification. Methylprednisolone is a synthetic glucocorticoid — a corticosteroid, not an anabolic steroid. It sits in WADA class S9, prohibited in-competition only, and belongs to the Specified Substances group. The distinction is not academic. Specified Substances are recognised as more plausibly linked to inadvertent or therapeutic use. That is why the baseline sanction is typically two years, and why a therapeutic defence is a real pathway. Russia 2026, I watched the data shatter before my eyes. The lesson I kept from it was not to distrust data, but to check the label people stick on it. A substance called by the wrong name produces a sanction understood wrongly, and a sanction understood wrongly produces a lesson drawn wrongly. Aga's side offered an explanation: she used the substance to treat a knee injury. That is a medically coherent scenario. Glucocorticoids are widely used anti-inflammatories in sport, including intra-articular injection. The problem lies in three places: the route of administration is not stated in the source, the timing relative to competition is not stated, and no valid Therapeutic Use Exemption is cited. Those three blanks, added together, are enough to turn a potentially legitimate treatment case into a confirmed violation. The six-year sanction is not an arbitrary figure. It is the sum of two years for presence and four years for tampering with results management, served consecutively rather than concurrently. The WADA Code is explicit on this — multiple independent violations accumulate, they do not run in parallel. What is striking is the ratio. The penalty for forging documents is double the penalty for the substance itself. In other words, the system rates concealment as more serious than the underlying act — a deliberate design choice, not an error. An athlete who uses a prohibited substance for therapeutic reasons and discloses honestly faces a lighter path: two years, possibly none at all with a retroactive TUE. An athlete who fabricates documents closes that path permanently. The evidence chain here is remarkably airtight. Investigators verified the clinic on the slip — it does not exist. They checked the signatory's registration — none exists. They contacted the facility that supposedly employed the signatory and supplied the old pad — it confirmed the person was never staff. They contacted the impersonated clinic — it denied the prescription was theirs. Four checks, four denials. There is no gap for a defence lawyer to enter. Data does not create stories; it strips the stories of others. Here, the data stripped a story that was built too clumsily. You did not need a skilled anti-doping investigator to spot a clinic that does not exist. You needed one phone call. The question I keep asking is why an athlete at the very top of world road running had nobody beside her capable of saying: don't do this. A sports lawyer, a compliance adviser, a representative experienced in doping cases — any of them would know forged medical documents are the first thing checked and the fastest thing caught. The most likely answer is that there was nobody. This is the point I want to stress, because it differs from how the story is usually told. This file does not describe a sophisticated doping system. It describes a gap in the support system. East African distance runners often compete on invitation contracts, move across countries, and work with small training groups and thin agent networks. That structure is optimised for earning appearance fees, not for managing legal crises. When a crisis arrives, people call a relative. And the relative, in this case, did what a relative without expertise would do: tried to patch it with paper. The economics of road racing clarify the setting. Invitational half marathons and marathons in China are a significant revenue stream for East African athletes. Appearance fees, prize money, short-term contracts — real income lines, often larger than official championship earnings. They are also races with lower testing density than the World Marathon Majors, and often far from an athlete's familiar medical support. The March result will almost certainly be annulled, along with its prize money. That is an economic consequence, not merely a sporting one. Competitively, the effect of this ban is close to zero. Ethiopia's road-running pipeline is deep enough that one athlete removed from the start line barely registers on a leaderboard. Aga is one knot in a very dense net. She matters to her own career, her own contracts, her own followers — not to the balance of women's marathon running. That is why I do not treat this as a performance story. It is a governance story. I collect mistakes, classify them, and then I know where the team is heading. Here, the mistakes classify into two layers. The first is a medical error that is potentially forgivable: using an in-competition prohibited substance without an exemption. The second is a governance error that is not: fabricating documents to cover the first. The WADA system is designed to handle the first layer with an exit mechanism. It is designed to handle the second with a penalty that has no exit. Now I must write the case for the opposite direction, because an analysis with only one direction is a poor analysis. The counter-argument runs: six years is disproportionate. The substance was a corticosteroid, not a performance enhancer in the ordinary sense. There is no evidence Aga used it to run faster. The person who forged the document was not her, but a relative without expertise. In many legal systems, a third party's conduct is not fully attributed to the defendant. And morally, the distance between an athlete concealing anti-inflammatory use and an athlete concealing an organised doping programme is enormous. That argument carries weight. It is not enough to overturn the ruling, but it is enough to raise a design question: does the tampering penalty create a perverse effect, where the more frightened an athlete is, the more likely they are to forge, and the more they forge, the harder they are punished? I have no answer to that. But I know that in this file, the determinant of the sentence was not the substance. It was the paper. Those four extra years were added because of a clinic that does not exist. There is another risk worth naming, and it bears directly on how this story will be read. The steroid label in many reports inflates perceived severity for general readers. Ordinary readers do not distinguish a corticosteroid from an anabolic steroid. The result is that an anti-inflammatory case reads as a muscle-building case. The distance between those two readings is the distance between twenty years and a two-year suspended sentence in the public imagination. The second risk is over-generalisation. An amateur, clumsy case carried out by one individual and her family is easily read as evidence of a systemic problem. The evidence in the file does not support that reading. On the contrary, the clumsiness itself — a non-existent clinic, an unregistered signatory, an old pad — shows this was not an organised programme. An organised programme would not leave four easily checkable holes. I learned something in the 2026 season, when I had to rebuild Cerezo Osaka's pressing data from video because I could not attend the stadium. I predicted a form drop without home crowds. They finished fourth. I was wrong, and I had to add a variable to the model rather than blame the weather. The lesson applies here: the unmeasured variables in this file — route of administration, timing, the specific year of the positive test, whether Aga appeals to CAS — are all gaps that must be labelled as gaps, not filled with speculation. Every probability conceals a shock — I only make sure it does not repeat. So which signals matter in the next cycle? First, the entourage layer. Tampering cases often pull in investigations of those who helped construct the file. The source does not address the legal consequences for the relative who signed the slip. In some jurisdictions that conduct can be pursued separately, both criminally and on registration grounds. Second, retrospective review. Once a tampering finding is established, stored samples and biological passport data are often revisited. The probability is low, but not zero. Third, the reaction of the race market. Organisers on invitational circuits may tighten medical and documentary vetting for invited athletes as reputational self-protection. A small change, but one that could spread, and it will affect more people than one athlete. Fourth, the support-capacity question. The Ethiopian federation and the national anti-doping body may face pressure to provide guidance on therapeutic use exemptions and results-management procedure for their athletes. This is slow change, but the highest practical value on the list. What I keep from this file is not the six-year ban. It is the gap between two numbers: two and four. An athlete might have lost only two years if she, or someone beside her, had chosen to tell the truth about an old prescription pad. She lost six because she chose otherwise. Aga's career will end at 38, if she even wants to return. The market will not wait. The invitational races will not wait. But the system will — and the system has recorded that chain of four denials permanently, as a reminder that in the age of digitised records, the price of a forged slip is no longer measured by the slip itself.